Scopolamine API Market, by Form (Powder and Liquid), by Purity (≥99% and ≥ 98%), by Scale of Production (Industrial scale, Pilot scale, and Laboratory scale), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Oct 2022

Code : CMI5270

Pages :202

Formats :

Excel and PDF

Industry : Pharmaceutical

Scopolamine API MarketSize and Trends

The global scopolamine API market is estimated to be valued at US$ 292.96 million in 2022 and is expected to exhibit a CAGR of 5.3% during the forecast period (2022-2030).

Figure 1. Global Scopolamine API Market Share (%), by Form, 2022

Increasing number of surgeries globally is expected to drive growth of the scopolamine API market

Scopolamine is used as a medication for treating postoperative nausea and vomiting. Thus the rising number of surgeries is expected to drive the market growth over the forecast period. For instance, according to the news provided by the Asiri Central’s Brain and Spine Centre, in March 2020, Colombo marked a significant milestone recently of having performed 10,000 neurosurgical procedures since it was established in June 2010. The hospital has treated an average of 1,000 patients per year over the past five years

Figure 2. Global Scopolamine API Market Share (%), by Purity, 2022

Increasing product launch by key players in the market is expected to drive the market growth during the forecast period.

The key players in the market are adopting organic growth strategies such as product launch, which is expected to drive the market growth over the forecast period. For instance, in October 2019, Perrigo Company plc, an over-the-counter consumer goods and specialty pharmaceutical company, announced the relaunch of the AB-rated generic equivalent of Transderm Scop (scopolamine 1.5 mg), used to treat the symptoms of nausea or vomiting.